| 付倩雨,吴小和.抗心力衰竭药物研究进展及心力衰竭全程管理[J].中国临床保健杂志,2021,24(4):441-446. |
| 抗心力衰竭药物研究进展及心力衰竭全程管理 |
| Progress on prevention and treatment of elderly patients with heart failure and its whole-process management |
| 投稿时间：2021-01-04 |
| DOI：10.3969/J.issn.1672-6790.2021.04.003 |
| 中文关键词: 心力衰竭 疾病管理 药物疗法 老年人 |
| 英文关键词: Heart failure Disease management Drug therapy Aged 〖FL |
| 基金项目: |
|
| 摘要点击次数: 3100 |
| 全文下载次数: 3838 |
| 中文摘要: |
| 心力衰竭是心血管疾病的终末期表现和最主要的死亡原因。老年人心力衰竭占总心力衰竭的三分之二。随着对心力衰竭认识的不断深入,治疗也从强心、利尿、扩血管药物转变为神经内分泌治疗。本文系统地回顾了心力衰竭治疗的历史变迁,并对目前新型的抗心力衰竭药物如血管紧张素受体脑啡肽酶抑制剂(ARNI)、钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)、可溶性鸟苷酸环化酶(SGC)刺激剂等做了详细的介绍,直面老年心力衰竭面临的挑战,指出对老年心力衰竭要利用老年医学多学科团队进行评估、随访等全程综合管理,以降低心力衰竭患者的死亡率,改善生活质量。 |
| 英文摘要: |
| Heart failure is the end-stage manifestation of cardiovascular disease and the leading cause of death.Elderly heart failure patients accounts for two thirds of the total patients with heart failure.With the deepening of knowledge on heart failure,the treatments have changed from cardiotonic,diuretic and vasodilator therapies to neuroendocrine therapy.We reviewed the history of heart failure treatment and introduce some current new cardiotonic drugs such as ARNI,SGLT-2,vericiguat in detail.In Face of the challenge for aged patients with heart failure,geriatric interdisciplinary team and evaluation as well as whole-process management including follow-up visits should be promoted in the treatment,so as to reduce the mortality rate of heart failure patients and improve their life quality. |
|
查看全文
|
| 关闭 |
|
|
|